Date: 2017-06-01
Type of information: Nomination
Compound: head of research & development, chief human resources officer, chief compliance officer
Company: Alexion Pharmaceuticals (USA - CT)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On June 1, 2017, Alexion Pharmaceuticals announced key additions to its executive leadership team effective June 5, 2017 . Reporting to Chief Executive Officer, Ludwig Hantson will be: John Orloff , Executive Vice President, Head of Research & Development, Anne-Marie Law , Executive Vice President, Chief Human Resources Officer, and Indrani Lall Franchini , J.D., Executive Vice President, Chief Compliance Officer.
John Orloff is a global R&D business leader with 20 years of experience in the biopharmaceutical industry and deep expertise spanning various stages of clinical and non-clinical development, including developing medicines for rare diseases. As Alexion's Head of R&D, Dr. Orloff will be focused on strengthening the clinical pipeline and research programs, enhancing R&D productivity, overseeing regulatory and medical affairs, and supporting business development. Dr. Martin Mackay , Alexion's current Head of R&D, will work with Dr. Orloff to ensure a smooth transition of Alexion's key pipeline programs, including the registration filings of Soliris® (eculizumab) for patients with refractory generalized myasthenia gravis and the ALXN1210 clinical development programs. Dr. Orloff joins Alexion from Novelion where he served as Executive Vice President, Head of Research & Development since November 2016 . Previously, he was Global Head of R&D and Chief Scientific Officer at Baxalta, where he advanced the company's pipeline and oversaw regulatory approval of 10 unique products and two devices over two years. He also held executive R&D roles with Baxter International, Merck Serono , Novartis and Merck Research Laboratories .
Financial terms:
Latest news:
Is general: Yes
